Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin for Inflammation and Epogen Dose in Hemodialysis
NCT02764736Withdrawn
- Sponsor
- Einstein Healthcare Network
- Start
- Mar 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of atorvastatin in chronic inflammation and anemia, sponsored by Einstein Healthcare Network. Primary endpoint: Epoetin alfa (Epogen) utilization at 24 weeks. Planned start Mar 2016; status: withdrawn.
02
Drugs
atorvastatin
03
Conditions
chronic inflammationanemia
Beyond the preview
Go deeper on NCT02764736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02764736.